A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples